{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:46:00Z","timestamp":1791935160669,"version":"4.3.4"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31970881, 92169104"],"award-info":[{"award-number":["31970881, 92169104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-00963-4","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T07:02:32Z","timestamp":1726470152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["CircRNA based multivalent neuraminidase vaccine induces broad protection against influenza viruses in mice"],"prefix":"10.1038","volume":"9","author":[{"given":"Xinyu","family":"Yue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sizhe","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiran","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanmei","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyu","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yikai","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingchen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoting","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2000-7053","authenticated-orcid":false,"given":"Caijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4110-4776","authenticated-orcid":false,"given":"Ke-Wei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-0916","authenticated-orcid":false,"given":"Yuelong","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4659-1550","authenticated-orcid":false,"given":"Yao-Qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"963_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.it.2023.11.001","volume":"45","author":"NC Wu","year":"2024","unstructured":"Wu, N. C. & Ellebedy, A. H. Targeting neuraminidase: the next frontier for broadly protective influenza vaccines. Trends Immunol. 45, 11\u201319 (2024).","journal-title":"Trends Immunol."},{"key":"963_CR2","doi-asserted-by":"publisher","first-page":"e0233217","DOI":"10.1128\/mBio.02332-17","volume":"9","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines? mBio 9, e0233217 (2018).","journal-title":"mBio"},{"key":"963_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1080\/14760584.2024.2343689","volume":"23","author":"X Zhang","year":"2024","unstructured":"Zhang, X. & Ross, T. M. Anti-neuraminidase immunity in the combat against influenza. Expert Rev. Vaccines 23, 474\u2013484 (2024).","journal-title":"Expert Rev. Vaccines"},{"key":"963_CR4","doi-asserted-by":"publisher","unstructured":"Giurgea, L. T., Morens, D. M., Taubenberger, J. K. & Memoli, M. J. Influenza neuraminidase: a neglected protein and its potential for a better influenza vaccine. Vaccines 8, https:\/\/doi.org\/10.3390\/vaccines8030409 (2020).","DOI":"10.3390\/vaccines8030409"},{"key":"963_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cell.2018.03.030","volume":"173","author":"YQ Chen","year":"2018","unstructured":"Chen, Y. Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417\u2013429.e410 (2018).","journal-title":"Cell"},{"key":"963_CR6","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/s41586-023-06136-y","volume":"618","author":"C Momont","year":"2023","unstructured":"Momont, C. et al. A pan-influenza antibody inhibiting neuraminidase via receptor mimicry. Nature 618, 590\u2013597 (2023).","journal-title":"Nature"},{"key":"963_CR7","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.immuni.2023.07.004","volume":"56","author":"L Hansen","year":"2023","unstructured":"Hansen, L. et al. Human anti-N1 monoclonal antibodies elicited by pandemic H1N1 virus infection broadly inhibit HxN1 viruses in vitro and in vivo. Immunity 56, 1927\u20131938.e1928 (2023).","journal-title":"Immunity"},{"key":"963_CR8","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.immuni.2023.10.005","volume":"56","author":"R Lei","year":"2023","unstructured":"Lei, R. et al. Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase. Immunity 56, 2621\u20132634.e2626 (2023).","journal-title":"Immunity"},{"key":"963_CR9","doi-asserted-by":"publisher","unstructured":"Lederhofer, J. et al. Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase. Immunity, https:\/\/doi.org\/10.1016\/j.immuni.2024.02.003 (2024).","DOI":"10.1016\/j.immuni.2024.02.003"},{"key":"963_CR10","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1126\/science.aay0678","volume":"366","author":"D Stadlbauer","year":"2019","unstructured":"Stadlbauer, D. et al. Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science 366, 499\u2013504 (2019).","journal-title":"Science"},{"key":"963_CR11","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01421-21","volume":"96","author":"J Tan","year":"2022","unstructured":"Tan, J. et al. Human anti-neuraminidase antibodies reduce airborne transmission of clinical influenza virus isolates in the Guinea Pig Model. J. Virol. 96, e0142121 (2022).","journal-title":"J. Virol."},{"key":"963_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01057-23","volume":"97","author":"M McMahon","year":"2023","unstructured":"McMahon, M. et al. Immunity induced by vaccination with recombinant influenza B virus neuraminidase protein breaks viral transmission chains in guinea pigs in an exposure intensity-dependent manner. J. Virol. 97, e0105723 (2023).","journal-title":"J. Virol."},{"key":"963_CR13","doi-asserted-by":"publisher","first-page":"e00417","DOI":"10.1128\/mBio.00417-16","volume":"7","author":"MJ Memoli","year":"2016","unstructured":"Memoli, M. J. et al. Evaluation of antihemagglutinin and antineuraminidase antibodies as correlates of protection in an influenza A\/H1N1 virus healthy human challenge model. mBio 7, e00417\u201300416 (2016).","journal-title":"mBio"},{"key":"963_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00486-w","volume":"7","author":"S Strohmeier","year":"2022","unstructured":"Strohmeier, S. et al. A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice. NPJ Vaccines 7, 81 (2022).","journal-title":"NPJ Vaccines"},{"key":"963_CR15","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S0264-410X(97)00279-X","volume":"16","author":"BE Johansson","year":"1998","unstructured":"Johansson, B. E., Matthews, J. T. & Kilbourne, E. D. Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16, 1009\u20131015 (1998).","journal-title":"Vaccine"},{"key":"963_CR16","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02241-21","volume":"12","author":"S Strohmeier","year":"2021","unstructured":"Strohmeier, S. et al. A novel recombinant influenza virus neuraminidase vaccine candidate stabilized by a measles virus phosphoprotein tetramerization domain provides robust protection from virus challenge in the mouse model. mBio 12, e0224121 (2021).","journal-title":"mBio"},{"key":"963_CR17","doi-asserted-by":"publisher","first-page":"e1009171","DOI":"10.1371\/journal.ppat.1009171","volume":"17","author":"J Gao","year":"2021","unstructured":"Gao, J. et al. Balancing the influenza neuraminidase and hemagglutinin responses by exchanging the vaccine virus backbone. PLoS Pathog. 17, e1009171 (2021).","journal-title":"PLoS Pathog."},{"key":"963_CR18","doi-asserted-by":"crossref","unstructured":"Broecker, F. et al. Extending the stalk enhances immunogenicity of the influenza virus neuraminidase. J. Virol. 93, 10\u20131128 (2019).","DOI":"10.1128\/JVI.00840-19"},{"key":"963_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00420-6","volume":"6","author":"S Chivukula","year":"2021","unstructured":"Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines 6, 153 (2021).","journal-title":"NPJ Vaccines"},{"key":"963_CR20","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.ymthe.2020.04.018","volume":"28","author":"AW Freyn","year":"2020","unstructured":"Freyn, A. W. et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 28, 1569\u20131584 (2020).","journal-title":"Mol. Ther."},{"key":"963_CR21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2206333119","volume":"119","author":"M McMahon","year":"2022","unstructured":"McMahon, M. et al. Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses. Proc. Natl. Acad. Sci. USA 119, e2206333119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"963_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32149-8","volume":"13","author":"N Pardi","year":"2022","unstructured":"Pardi, N. et al. Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nat. Commun. 13, 4677 (2022).","journal-title":"Nat. Commun."},{"key":"963_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05096-6","volume":"9","author":"RA Wesselhoeft","year":"2018","unstructured":"Wesselhoeft, R. A., Kowalski, P. S. & Anderson, D. G. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat. Commun. 9, 2629 (2018).","journal-title":"Nat. Commun."},{"key":"963_CR24","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1016\/j.cell.2022.03.044","volume":"185","author":"L Qu","year":"2022","unstructured":"Qu, L. et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell 185, 1728\u20131744.e1716 (2022).","journal-title":"Cell"},{"key":"963_CR25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2302191120","volume":"120","author":"L Amaya","year":"2023","unstructured":"Amaya, L. et al. Circular RNA vaccine induces potent T cell responses. Proc. Natl. Acad. Sci. USA 120, e2302191120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"963_CR26","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jcv.2019.08.009","volume":"119","author":"JM Jansen","year":"2019","unstructured":"Jansen, J. M., Gerlach, T., Elbahesh, H., Rimmelzwaan, G. F. & Saletti, G. Influenza virus-specific CD4+ and CD8+ T cell-mediated immunity induced by infection and vaccination. J. Clin. Virol. 119, 44\u201352 (2019).","journal-title":"J. Clin. Virol."},{"key":"963_CR27","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41590-019-0320-6","volume":"20","author":"M Koutsakos","year":"2019","unstructured":"Koutsakos, M. et al. Human CD8+ T cell cross-reactivity across influenza A, B and C viruses. Nat. Immunol. 20, 613\u2013625 (2019).","journal-title":"Nat. Immunol."},{"key":"963_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc9937","volume":"8","author":"K van de Ven","year":"2022","unstructured":"van de Ven, K. et al. A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets. Sci. Adv. 8, eadc9937 (2022).","journal-title":"Sci. Adv."},{"key":"963_CR29","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41579-021-00642-4","volume":"19","author":"M Koutsakos","year":"2021","unstructured":"Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 19, 741\u2013742 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"963_CR30","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.vaccine.2014.01.078","volume":"32","author":"I Sultana","year":"2014","unstructured":"Sultana, I. et al. Stability of neuraminidase in inactivated influenza vaccines. Vaccine 32, 2225\u20132230 (2014).","journal-title":"Vaccine"},{"key":"963_CR31","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1093\/cid\/ciz1198","volume":"71","author":"CD Weiss","year":"2020","unstructured":"Weiss, C. D. et al. Neutralizing and neuraminidase antibodies correlate with protection against influenza during a late season A\/H3N2 outbreak among unvaccinated military recruits. Clin. Infect. Dis. 71, 3096\u20133102 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"963_CR32","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis935","volume":"207","author":"RB Couch","year":"2013","unstructured":"Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207, 974\u2013981 (2013).","journal-title":"J. Infect. Dis."},{"key":"963_CR33","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586, 567\u2013571 (2020).","journal-title":"Nature"},{"key":"963_CR34","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"963_CR35","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","volume":"182","author":"NN Zhang","year":"2020","unstructured":"Zhang, N. N. et al. A Thermostable mRNA Vaccine against COVID-19. cell 182, 1271\u20131283.e1216 (2020).","journal-title":"cell"},{"key":"963_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","volume":"378","author":"CP Arevalo","year":"2022","unstructured":"Arevalo, C. P. et al. A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes. Science 378, 899\u2013904 (2022).","journal-title":"Science"},{"key":"963_CR37","doi-asserted-by":"publisher","first-page":"19123","DOI":"10.1073\/pnas.0607614103","volume":"103","author":"A Harris","year":"2006","unstructured":"Harris, A. et al. Influenza virus pleiomorphy characterized by cryoelectron tomography. Proc. Natl. Acad. Sci. USA 103, 19123\u201319127 (2006).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"963_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112766","volume":"42","author":"D-J Liu","year":"2023","unstructured":"Liu, D.-J. et al. Boost immunizations with NA-derived peptide conjugates achieve induction of NA inhibition antibodies and heterologous influenza protections. Cell Rep. 42, 112766 (2023).","journal-title":"Cell Rep."},{"key":"963_CR39","doi-asserted-by":"crossref","unstructured":"Rajendran, M. et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin. mBio 8, 10\u20131128 (2017).","DOI":"10.1128\/mBio.02281-16"},{"key":"963_CR40","doi-asserted-by":"crossref","unstructured":"Walz, L., Kays, S. K., Zimmer, G. & von Messling, V. Neuraminidase-Inhibiting antibody titers correlate with protection from heterologous influenza virus strains of the same neuraminidase subtype. J. Virol. 92, 10\u20131128 (2018).","DOI":"10.1128\/JVI.01006-18"},{"key":"963_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-3083.2005.01633.x","volume":"62","author":"AO Hovden","year":"2005","unstructured":"Hovden, A. O., Cox, R. J. & Haaheim, L. R. Whole influenza virus vaccine is more immunogenic than split influenza virus vaccine and induces primarily an IgG2a response in BALB\/c mice. Scand. J. Immunol. 62, 36\u201344 (2005).","journal-title":"Scand. J. Immunol."},{"key":"963_CR42","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1086\/314952","volume":"180","author":"TM Moran","year":"1999","unstructured":"Moran, T. M., Park, H., Fernandez-Sesma, A. & Schulman, J. L. Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J. Infect. Dis. 180, 579\u2013585 (1999).","journal-title":"J. Infect. Dis."},{"key":"963_CR43","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1128\/jvi.71.6.4347-4355.1997","volume":"71","author":"K Mozdzanowska","year":"1997","unstructured":"Mozdzanowska, K., Furchner, M., Washko, G., Mozdzanowski, J. & Gerhard, W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J. Virol. 71, 4347\u20134355 (1997).","journal-title":"J. Virol."},{"key":"963_CR44","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.abb8923","volume":"368","author":"BS Graham","year":"2020","unstructured":"Graham, B. S. Rapid COVID-19 vaccine development. Science 368, 945\u2013946 (2020).","journal-title":"Science"},{"key":"963_CR45","doi-asserted-by":"publisher","first-page":"e1010755","DOI":"10.1371\/journal.ppat.1010755","volume":"18","author":"KH Kim","year":"2022","unstructured":"Kim, K. H. et al. Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle. PLoS Pathog. 18, e1010755 (2022).","journal-title":"PLoS Pathog."},{"key":"963_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms8708","volume":"6","author":"Y Wu","year":"2015","unstructured":"Wu, Y. et al. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat. Commun. 6, 7708 (2015).","journal-title":"Nat. Commun."},{"key":"963_CR47","doi-asserted-by":"publisher","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. e51112, https:\/\/doi.org\/10.3791\/51112 (2013).","DOI":"10.3791\/51112"},{"key":"963_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2022.105370","volume":"204","author":"C Seephetdee","year":"2022","unstructured":"Seephetdee, C. et al. A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antivir. Res. 204, 105370 (2022).","journal-title":"Antivir. Res."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00963-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00963-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00963-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T08:20:57Z","timestamp":1726647657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-00963-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["963"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-00963-4","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"assertion":[{"value":"6 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors utilized ChatGPT 3.5 to enhance grammar and readability during the manuscript writing. Following this, the authors thoroughly reviewed and edited the article, assuming full responsibility for its content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of the use of Artificial Intelligence (AI) assisted technology in the manuscript writing"}},{"value":"The Mice experiment proposal was examined and approved by the Institutional Animal Care and Use Committee (IACUC) from the Shenzhen Bay Laboratory. (Ethics File Code: AECYQ202201). Mice experiments were performed according to the animal welfare requirements of Shenzhen Bay Laboratory. Mice influenza virus challenge experiments were performed in the animal biosafety level 2 (ABSL-2) facility at Shenzhen Bay Laboratory.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"170"}}